BVF Partners L.P. disclosed a 9.99% stake in Entera Bio Ltd.’s ordinary shares. The group filed a Schedule 13D on Aug. 4, 2026 following two private placements in April and July. The move gives BVF direct board influence and signals a hands-on role in Entera Bio’s governance.Investor IntentUnder th…
TEL AVIV, July 31, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. NASDAQ:ENTX (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that the Company’s Chief Executive Officer, Miranda Toledano, will be participating in a fireside chat at the Canaccord Genuity 46th Ann…
MIAMI, July 29, 2026 /PRNewswire/ -- Global law firm Greenberg Traurig, P.A. advised Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of oral peptides, in connection with its oversubscribed $275 million private placement financing.The financing is expected to extend Entera Bio's cash runw…
Entera Bio completed a market-priced private placement, raising approximately $275 million at $2.04 per share through a mix of ordinary shares and pre-funded warrants. The offering closed on Jul 28, 2026, with 122,961,215 shares and 11,842,695 pre-funded warrants issued, and includes BVF board desi…
Entera Bio said that directors Haya Taitel and Yonatan Malca will resign or not stand for reelection effective upon appointment or election of corresponding new independent directors under its succession plan.Original SEC Filing: Entera Bio Ltd. [ ENTX ] - 8-K - Jul. 28, 2026This is an AI-powered s…
WSW, NY, July 8th, 2026, FinanceWireA new national study just put hard numbers on a treatment gap most Americans have never heard of. One microcap, Entera NASDAQ:ENTX has a proprietary oral peptide platform, an advancing pipeline, and a lead candidate that might close this exact gapA slip on a wet…
